The Japan Science Technology Agency (JST) made an additional investment in Provigate Inc. (Headquarters in Tokyo; President and CEO: Koshin Sekimizu) under the Support Program of Capital Contribution to Early-Stage Companies (SUCCESS).

Provigate develops and provides biosensors, post-in monitoring systems, and application software for supporting behavioral changes in people with diabetes and pre-diabetes, with a focus on glycoalbumin (GA), which sensitively reflects blood glucose fluctuations for up to a week.

Through industry–government–academia collaborations, Provigate is promoting open innovation and aiming for the implementation and global standardization of blood glucose monitoring in society by integrating once-weekly at-home GA monitoring along with an app for tracking behavioral changes.

Provigate, established in March 2015, is a medical and engineering collaborative start-up that originated from the University of Tokyo. The company has been advancing further research using the research findings of Dr. Toshiya Sakata, Associate Professor at the University of Tokyo and co-founder and Outside Director of Provigate, under the JST’s programs. The programs are as follows: Strategic Basic Research Programs CREST “Bio-transistors with Bio-Functional Nano-Structured Gates” (Research section leader Toshiya Sakata, adopted in FY2008); JST-SENTAN Development of Advanced Measurement and Analysis Systems Program “Single-chip genome analysis by semiconductor biosensing technology” (Team Leader Toshiya Sakata, adopted in FY2008); and JST-Mirai Program “Realization of health monitoring service with semiconductor-based biosensor” (Principle Investigator Toshiya Sakata, adopted in FY2017). SUCCESS has supported Provigate since April 2021.